The company said, “This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage constant exchange rate revenue growth. Bruker (BRKR) estimates non-GAAP organic revenue growth in the first quarter to be in the low-single digit percentages, with mid-single digit percentage organic revenue growth in the Bruker Scientific Instrument segment, and a high-teens percentage organic revenue decline in the BEST segment, net of intercompany eliminations.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker price target lowered to $50 from $60 at Barclays
- Bruker announces launch of Fourier 80 FT-NMR spectrometer
- Bruker price target lowered to $50 from $75 at Citi
- Bruker’s Strong Market Position and Growth Potential Drive Buy Rating
- Bruker Corporation: A Strategic Buy Amid Market Concerns and Growth Opportunities